Multicriteria Decision Analysis (MCDA) In HTA - Pilot Study in the Czech Republic
Value Health
.
2014 Nov;17(7):A439.
doi: 10.1016/j.jval.2014.08.1143.
Epub 2014 Oct 26.
Authors
P Hajek
1
,
L Pecen
2
,
L Bulejova
3
,
M Cook
4
,
T Dolezal
5
,
J Dolezel
6
,
J Duba
7
,
I Dukova
8
,
L Fuksa
9
,
M Heislerova
10
,
K Jaskova
8
,
P Karasek
11
,
J Klimes
12
,
A Kminek
13
,
Z Kucera
14
,
Š Vesela
15
,
P Vothova
1
,
J Svihovec
10
Affiliations
1
Pfizer s r. o., Prague, Czech Republic.
2
CEEOR s. r. o., Prague, Czech Republic.
3
InterMune, Muttenz, Switzerland.
4
BAYER s. r. o., Prague, Czech Republic.
5
VALUE OUTCOMES, Prague, Czech Republic.
6
GlaxoSmithKline, s. r. o., Prague, Czech Republic.
7
OAKS Consulting s. r. o., Prague 9, Czech Republic.
8
Merck, Prague, Czech Republic.
9
General Health Insurance Company of the Czech Republic, Praha, Czech Republic.
10
University Hospital in Motol, Prague, Czech Republic.
11
Novartis s. r. o., Prague, Czech Republic.
12
iHETA, Prague, Czech Republic.
13
AstraZeneca, Prague, Czech Republic.
14
Sanofi-Aventis, Prague, Czech Republic.
15
Janssen, Prague, Czech Republic.
PMID:
27201174
DOI:
10.1016/j.jval.2014.08.1143
No abstract available